rabeprazole (Aciphex)
Jump to navigation
Jump to search
Introduction
Tradename: Aciphex. Generic approved nov 2013.[2]
Indications
- duodenal ulcer
- gastroesophageal reflux disease (GERD)
- prevention of GI bleed due to hypersecretory conditions
- reflux esophagitis (treatment & maintenance)
- component of combination therapy for Helicobacter pylori
Dosage
Tabs: 20 mg (delayed release).
Mechanism of action
- proton pump inhibitor
- interacts with sulfhydryl groups in proton pump
- inactive at neutral pH
More general terms
References
- ↑ Kaiser Permanente Northern California Drug Information, 2000
- ↑ 2.0 2.1 FDA News Release: Nov. 8, 2013 FDA approves first generic versions of Aciphex delayed-release tablets to treat GERD. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm374329.htm
- ↑ 3.0 3.1 Deprecated Reference
- ↑ Gu L, Li S, He Y, Chen Y, Jiang Y, Peng Y, Liu X, Yang H. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study. Helicobacter. 2019 Aug;24(4):e12594. PMID: https://pubmed.ncbi.nlm.nih.gov/31119830
- ↑ Kilic G, Kilic GE, Ozkahraman A, Konur S, Dertli R, Kayar Y Amoxicillin, gemifloxacin and rabeprazole, as first-line Helicobacter pylori therapy in clinical practice: A pilot study. Medicine (Baltimore). 2024 May 3;103(18):e38012. PMID: https://pubmed.ncbi.nlm.nih.gov/38701320 PMCID: PMC11062647 Free PMC article.
- ↑ Wang Y, Dai X, Gao C, Yang X. Network meta-analysis of different dosages of esomeprazole and rabeprazole for the treatment of Helicobacter pylori. PMID: https://pubmed.ncbi.nlm.nih.gov/36645422
- ↑ Jung BW, Park CH, Jung YS. Efficacy and safety of tegoprazan- and rabeprazole-based concomitant therapies for Helicobacter pylori infection: Real-world evidence. J Gastroenterol Hepatol. 2024 Nov;39(11):2409-2416. PMID: https://pubmed.ncbi.nlm.nih.gov/39188111